NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. Show more

Location: 3001 Daimler Street, Santa Ana, CA, 92705, United States | Website: https://nkgenbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

24.67M

52 Wk Range

$0.10 - $1.37

Previous Close

$0.33

Open

$0.33

Volume

400,881

Day Range

$0.28 - $0.38

Enterprise Value

45.56M

Cash

8.00K

Avg Qtr Burn

-5.217M

Insider Ownership

107.29%

Institutional Own.

1.66%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.